{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:58:37Z","timestamp":1790657917329,"version":"4.1.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Refractory chronic cough and unexplained chronic cough are increasingly understood as clinical expressions of cough hypersensitivity. P2X3 receptor antagonists have been developed to reduce ATP-mediated airway sensory nerve activation, but their benefit must be balanced against taste-related adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Randomized placebo-controlled trials evaluating oral P2X3 receptor antagonists in adults with refractory or unexplained chronic cough were included. Objective cough frequency and taste-related adverse events were selected as primary efficacy and safety\/tolerability outcomes. Secondary outcomes included Leicester Cough Questionnaire (LCQ) total score, cough severity visual analogue scale (VAS), overall adverse events, and discontinuation due to adverse events. Effects were pooled using random-effects inverse-variance models. Sensitivity analyses, publication-bias assessment, and GRADE certainty ratings were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eleven trial reports involving 3568 participants were included, yielding 13 independent comparisons for objective cough frequency. P2\u00d73 receptor antagonists reduced objective cough frequency compared with placebo (ratio 0.71, 95% CI 0.63\u20130.79), corresponding to a 29.3% relative reduction. They also improved LCQ total score (MD 1.44, 95% CI 0.78\u20132.09) and cough severity VAS (MD -12.73 mm, 95% CI -17.10 to \u22128.36). Taste-related adverse events were increased (RR 7.36, 95% CI 4.84\u201311.21), as were overall adverse events (RR 1.21, 95% CI 1.07\u20131.38) and discontinuation due to adverse events (RR 3.62, 95% CI 2.65\u20134.93). Leave-one-out analyses did not alter the direction of any pooled estimate. Egger and Begg tests suggested small-study effects for objective cough frequency, but not for safety outcomes with sufficient comparisons. The certainty of evidence was rated as moderate for all prespecified outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>P2\u00d73 receptor antagonists were associated with reductions in objective cough frequency and improvements in patient-reported outcomes in refractory or unexplained chronic cough. These benefits should be balanced against increased safety and tolerability concerns, especially taste disturbance, although receptor selectivity appears to attenuate this risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier CRD420261422476.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1911091","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:37:28Z","timestamp":1790656648000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of P2X3 receptor antagonists in refractory or unexplained chronic cough: an updated systematic review and meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Yu-Tong","family":"An","sequence":"first","affiliation":[{"name":"Hunan University of Chinese Medicine","place":["Changsha, China"]},{"name":"Affiliated Hospital of Hunan Academy of Chinese Medicine","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Ze","family":"Tang","sequence":"additional","affiliation":[{"name":"Hunan University of Chinese Medicine","place":["Changsha, China"]},{"name":"Affiliated Hospital of Hunan Academy of Chinese Medicine","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Luo","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Hunan Academy of Chinese Medicine","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Huang","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Hunan Academy of Chinese Medicine","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-Juan","family":"Deng","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Hunan Academy of Chinese Medicine","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/S0140-6736(14)61255-1","article-title":"P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study","volume":"385","author":"Abdulqawi","year":"2015","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"B3","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"B4","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1136\/thorax.58.4.339","article-title":"Development of a symptom specific health status measure for patients with chronic cough: Leicester cough questionnaire (LCQ)","volume":"58","author":"Birring","year":"2003","journal-title":"Thorax"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1183\/09031936.00057407","article-title":"The Leicester cough monitor: preliminary validation of an automated cough detection system in chronic cough","volume":"31","author":"Birring","year":"2008","journal-title":"Eur. Respir. J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1177\/0194599818768517","article-title":"Short- and long-term effects of neuromodulators for unexplained chronic cough","volume":"159","author":"Bowen","year":"2018","journal-title":"Otolaryngol. Head. Neck Surg."},{"key":"B7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1136\/thoraxjnl-2016-208843","article-title":"Physiotherapy, and speech and language therapy intervention for patients with refractory chronic cough: a multicentre randomised control trial","volume":"72","author":"Chamberlain Mitchell","year":"2017","journal-title":"Thorax"},{"key":"B8","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/S2213-2600(13)70043-2","article-title":"Chronic cough as a neuropathic disorder","volume":"1","author":"Chung","year":"2013","journal-title":"Lancet Respir. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin. Trials"},{"key":"B10","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00408-023-00621-x","article-title":"Efficacy and safety of eliapixant in refractory chronic cough: the randomized, placebo-controlled phase 2b PAGANINI study","volume":"201","author":"Dicpinigaitis","year":"2023","journal-title":"Lung"},{"key":"B11","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1126\/science.1118435","article-title":"ATP signaling is crucial for communication from taste buds to gustatory nerves","volume":"310","author":"Finger","year":"2005","journal-title":"Science"},{"key":"B13","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3389\/fncel.2013.00267","article-title":"The therapeutic promise of ATP antagonism at P2X3 receptors in respiratory and urological disorders","volume":"7","author":"Ford","year":"2013","journal-title":"Front. Cell Neurosci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12931-023-02384-8","article-title":"The P2X3 receptor antagonist filapixant in patients with refractory chronic cough: a randomized controlled trial","volume":"24","author":"Friedrich","year":"2023","journal-title":"Respir. Res."},{"key":"B15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1378\/chest.15-1496","article-title":"Treatment of unexplained chronic cough: CHEST guideline and expert panel report","volume":"149","author":"Gibson","year":"2016","journal-title":"Chest"},{"key":"B16","unstructured":"GSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC)\n          \n          \n          2026"},{"key":"B17","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.ad","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"B18","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"B20","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1080\/17460441.2024.2391902","article-title":"The discovery and development of gefapixant as a novel antitussive therapy","volume":"19","author":"Matera","year":"2024","journal-title":"Expert Opin. Drug Discov."},{"key":"B22","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1152\/physrev.00039.2015","article-title":"Vagal afferent innervation of the airways in health and disease","volume":"96","author":"Mazzone","year":"2016","journal-title":"Physiol. Rev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/s0140-6736(21)02348-5","article-title":"Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials","volume":"399","author":"McGarvey","year":"2022","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00408-022-00592-5","article-title":"A randomized, double-blind, placebo-controlled, parallel-group phase 2b trial of P2X3 receptor antagonist sivopixant for refractory or unexplained chronic cough","volume":"201","author":"McGarvey","year":"","journal-title":"Lung"},{"key":"B25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00408-023-00606-w","article-title":"The efficacy and safety of gefapixant in a phase 3b trial of patients with recent-onset chronic cough","volume":"201","author":"McGarvey","year":"","journal-title":"Lung"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1183\/09031936.00101006","article-title":"ERS guidelines on the assessment of cough","volume":"29","author":"Morice","year":"2007","journal-title":"Eur. Respir. J."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1183\/09031936.00218613","article-title":"Expert opinion on the cough hypersensitivity syndrome in respiratory medicine","volume":"44","author":"Morice","year":"2014","journal-title":"Eur. Respir. J."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1901136","DOI":"10.1183\/13993003.01136-2019","article-title":"ERS guidelines on the diagnosis and treatment of chronic cough in adults and children","volume":"55","author":"Morice","year":"2020","journal-title":"Eur. Respir. J."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2004240","DOI":"10.1183\/13993003.04240-2020","article-title":"Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study","volume":"58","author":"Morice","year":"2021","journal-title":"Eur. Respir. J."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2100725","DOI":"10.1183\/13993003.00725-2021","article-title":"Randomised trial of the P2X3 receptor antagonist sivopixant for refractory chronic cough","volume":"59","author":"Niimi","year":"","journal-title":"Eur. Respir. J."},{"key":"B31","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.alit.2022.05.006","article-title":"A phase 3, randomized, double-blind, clinical study to evaluate the long-term safety and efficacy of gefapixant in Japanese adult participants with refractory or unexplained chronic cough","volume":"71","author":"Niimi","year":"","journal-title":"Allergol. Int."},{"key":"B32","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B33","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.anai.2024.12.021","article-title":"Therapeutic and mechanistic advances in chronic cough","volume":"134","author":"Peters","year":"2025","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/978-3-540-79842-2_16","article-title":"Clinical cough IV: what is the minimal important difference for the Leicester cough questionnaire?","volume":"187","author":"Raj","year":"2009","journal-title":"Handb. Exp. Pharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"102252","DOI":"10.1016\/j.pupt.2023.102252","article-title":"Safety and efficacy of P2X3 receptor antagonist for the treatment of refractory or unexplained chronic cough: a systematic review and meta-analysis of 11 randomized controlled trials","volume":"83","author":"Ramadan","year":"2023","journal-title":"Pulm. Pharmacol. Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1016\/S0140-6736(12)60776-4","article-title":"Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial","volume":"380","author":"Ryan","year":"2012","journal-title":"Lancet"},{"key":"B37","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jaip.2024.11.004","article-title":"The clinical approach to chronic cough","volume":"13","author":"Satia","year":"2025","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B38","doi-asserted-by":"crossref","first-page":"1901615","DOI":"10.1183\/13993003.01615-2019","article-title":"Gefapixant in two randomised dose-escalation studies in chronic cough","volume":"55","author":"Smith","year":"","journal-title":"Eur. Respir. J."},{"key":"B39","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/s2213-2600(19)30471-0","article-title":"Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial","volume":"8","author":"Smith","year":"","journal-title":"Lancet Respir. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00408-022-00553-y","article-title":"Improvements in objective and subjective measures of chronic cough with gefapixant: a pooled phase 3 efficacy analysis of predefined subgroups","volume":"200","author":"Smith","year":"2022","journal-title":"Lung"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1164\/rccm.202501-0093RL","article-title":"Camlipixant in refractory chronic cough: a phase 2a, randomized controlled trial (RELIEF)","volume":"211","author":"Smith","year":"","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1164\/rccm.202409-1752OC","article-title":"Camlipixant in refractory chronic cough: a phase 2b, randomized, placebo-controlled trial (SOOTHE)","volume":"211","author":"Smith","year":"","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1183\/09031936.00218714","article-title":"The global epidemiology of chronic cough in adults: a systematic review and meta-analysis","volume":"45","author":"Song","year":"2015","journal-title":"Eur. Respir. J."},{"key":"B44","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.jaip.2024.10.046","article-title":"Cough reflex hypersensitivity as a key treatable trait","volume":"13","author":"Song","year":"2025","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B45","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"B46","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s41687-025-00888-z","article-title":"Psychometric validation of the severity of chronic cough diary, Leicester cough questionnaire, and a cough severity visual analogue scale in patients with refractory chronic cough","volume":"9","author":"Trigg","year":"2025","journal-title":"J. Patient Rep. Outcomes"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1113\/jphysiol.2014.281014","article-title":"Postsynaptic P2X3-containing receptors in gustatory nerve fibres mediate responses to all taste qualities in mice","volume":"593","author":"Vandenbeuch","year":"2015","journal-title":"J. Physiol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1136\/thx.2006.064337","article-title":"Efficacy of speech pathology management for chronic cough: a randomised placebo controlled trial of treatment efficacy","volume":"61","author":"Vertigan","year":"2006","journal-title":"Thorax"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.chest.2024.05.015","article-title":"Benefit-risk profile of P2X3 receptor antagonists for treatment of chronic cough: dose-response model-based network meta-analysis","volume":"166","author":"Yamamoto","year":"2024","journal-title":"Chest"},{"key":"B50","doi-asserted-by":"crossref","first-page":"107336","DOI":"10.1016\/j.rmed.2023.107336","article-title":"Potential applications of P2X3 receptor antagonists in the treatment of refractory cough","volume":"217","author":"Yi","year":"2023","journal-title":"Respir. Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"102100","DOI":"10.1016\/j.eclinm.2023.102100","article-title":"Efficacy and safety of pharmacotherapy for refractory or unexplained chronic cough: a systematic review and network meta-analysis","volume":"62","author":"Zheng","year":"2023","journal-title":"EClinicalMedicine"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1911091\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:37:50Z","timestamp":1790656670000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1911091\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":51,"alternative-id":["10.3389\/fphar.2026.1911091"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1911091","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"article-number":"1911091"}}